Epiomic Epidemiology Series: Autism Spectrum Disorders Forecast in 22 Major Markets 2018–2028

March 2018 | 88 pages | ID: EE18065BE5EEN
Black Swan Analysis limited

Abstracts

Black Swan Analysis Epiomic Epidemiology Forecast Report on Autism Spectrum Disorders in 22 Major Markets

Autism Spectrum Disorders (ASD) or Pervasive Developmental Disorder (PDD) defines a group of developmental disability disorders. These disorders include: Autism, Pervasive Developmental Disorder not otherwise specified (PDD-NOS), Asperger syndrome, Rett syndrome and Childhood Disintegrative Disorder (CDD). The latter two are very rare and often absent from studies, and therefore not covered by this report.

Attributes of these disorders can be grouped into three areas: communication difficulties, repetitive and stereotyped behaviour, and social impairment. ASD is collectively called a “wide-spectrum” disorder due to the wide variation of symptoms which can occur in any given patient. The nature of these symptoms and their life-long duration constitute a serious burden to both the patients and their families, often limiting career prospects and personal life success.

This report provides the current prevalent population for autism spectrum disorders across 22 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Austria, Denmark, Sweden, Russia, Turkey, Japan, China, South Korea, Singapore, India, Australia, Brazil, Mexico) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several features of autism spectrum disorder patients, as well as the main symptoms and comorbidities of the disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of autism spectrum disorders include:

• ADHD
• Epilepsy (especially in ASD with intellectual disability)
• GI problems
• Restless Sleep
• Anxiety
• Depression
• Motor function / co-ordination problems
• Hypotonia

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Ability to quantify patient populations in global autism spectrum disorder market to target the development of future products, pricing strategies and launch plans.
• Further insight into the prevalence of the subdivided types of autism spectrum disorders and identification of patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Better understanding of the impact of specific co-morbid conditions on the prevalent population of autism spectrum disorder patients.
• Identification of autism spectrum disorder patient sub-populations that require treatment.
• Better understanding of the specific markets that have the largest number of autism spectrum disorder patients.

Contents

INTRODUCTION

CAUSE OF THE DISEASE

RISK FACTORS & PREVENTION

DIAGNOSIS OF THE DISEASE

VARIATION BY GEOGRAPHY/ETHNICITY

DISEASE PROGNOSIS & CLINICAL COURSE

KEY COMORBID CONDITIONS / FEATURES ASSOCIATED WITH THE DISEASE

METHODOLOGY FOR QUANTIFICATION OF PATIENT NUMBERS

TOP-LINE PREVALENCE FOR AUTISM SPECTRUM DISORDERS

FEATURES OF AUTISM SPECTRUM DISORDER PATIENTS

COMORBIDITIES OF AUTISM SPECTRUM DISORDERS PATIENTS

ABBREVIATIONS USED IN THE REPORT

OTHER BLACK SWAN SERVICES & SOLUTIONS

REPORTS & PUBLICATIONS

ONLINE EPIDEMIOLOGY DATABASES

ONLINE PHARMACEUTICAL PRICING DATABASE

REFERENCES

APPENDIX

List Of Tables

LIST OF TABLES AND FIGURES

Table 1. Classification of pervasive developmental disorders according to ICD-10 Version:2015
Table 2. DSM-5 diagnostic criteria for autism spectrum disorders
Table 3. Prevalence of autism spectrum disorders, total (000s)
Table 4. Prevalence of autism spectrum disorders, males (000s)
Table 5. Prevalence of autism spectrum disorders, females (000s)
Table 6. Patients with autism spectrum disorders by diagnosis, total (000s)
Table 7. Patients with autism spectrum disorders by cognitive function, total (000s)
Table 8. Patients with autism spectrum disorders by severity, total (000s)
Table 9. Patients with autism spectrum disorders by hours of sleep, total (000s)
Table 10. Patients with autism spectrum disorders by gastrointestinal symptoms, total (000s)
Table 11. Autism spectrum disorder patients with chronic diarrhoea, total (000s)
Table 12. Autism spectrum disorder patients with constipation, total (000s)
Table 13. Autism spectrum disorder patients with hypotonia, total (000s)
Table 14. Autism spectrum disorder patients with apraxia, total (000s)
Table 15. Autism spectrum disorder patients with toe-walking, total (000s)
Table 16. Autism spectrum disorder patients with gross motor delay, total (000s)
Table 17. Autism spectrum disorder patients with epilepsy, total (000s)
Table 18. Autism spectrum disorder patients with depressed mood or depression, total (000s)
Table 19. Autism spectrum disorder patients with anxiety, total (000s)
Table 20. Autism spectrum disorder patients with irritability, total (000s)
Table 21. Autism spectrum disorder patients with ADHD, total (000s)
Table 22. Autism spectrum disorder patients with difficulty falling asleep, total (000s)
Table 23. Autism spectrum disorder patients with restless sleep, total (000s)
Table 24. Abbreviations and acronyms used in the report
Table 25. USA prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 26. USA prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 27. Canada prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 28. Canada prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 29. France prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 30. France prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 31. Germany prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 32. Germany prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 33. Italy prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 34. Italy prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 35. Spain prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 36. Spain prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 37. UK prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 38. UK prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 39. Poland prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 40. Poland prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 41. Netherlands prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 42. Netherlands prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 43. Austria prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 44. Austria prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 45. Denmark prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 46. Denmark prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 47. Sweden prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 48. Sweden prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 49. Russia prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 50. Russia prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 51. Turkey prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 52. Turkey prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 53. Japan prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 54. Japan prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 55. China prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 56. China prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 57. South Korea prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 58. South Korea prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 59. Singapore prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 60. Singapore prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 61. India prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 62. India prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 63. Australia prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 64. Australia prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 65. Brazil prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 66. Brazil prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)
Table 67. Mexico prevalence of autism spectrum disorders by 5-yr age cohort, males (000s)
Table 68. Mexico prevalence of autism spectrum disorders by 5-yr age cohort, females (000s)